KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
11.14 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 12.69 | 12.69 | 16.127 | 8.394 | 1.504 | 2.133 | 1.804 | 0.415 | 1.538 |
| Cost of Revenue
| 0.816 | 0.802 | 0.743 | 0.651 | 0.04 | 0.035 | 0.018 | 0.013 | 0.015 | 0.008 | 0 | 0 |
| Gross Profit
| -0.816 | -0.802 | -0.743 | 12.039 | 12.65 | 16.092 | 8.376 | 1.491 | 2.118 | 1.796 | 0.415 | 1.538 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.949 | 0.997 | 0.998 | 0.998 | 0.992 | 0.993 | 0.995 | 1 | 1 |
| Reseach & Development Expenses
| 94.619 | 80.276 | 70.167 | 41.286 | 40.194 | 35.021 | 18.237 | 12.666 | 14.661 | 8.285 | 4.229 | 1.959 |
| General & Administrative Expenses
| 54.278 | 30.595 | 26.446 | 16.637 | 13.029 | 10.926 | 8.862 | 11.177 | 2.653 | 1.608 | 1.402 | 1.412 |
| Selling & Marketing Expenses
| -0.816 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 53.462 | 30.595 | 26.446 | 16.637 | 13.029 | 10.926 | 8.862 | 11.177 | 2.653 | 1.608 | 1.402 | 1.412 |
| Other Expenses
| 0 | 15.642 | 14.721 | 9.929 | 9.83 | 7.682 | 4.392 | 2.329 | 2.034 | 0.844 | -0.059 | 0.035 |
| Operating Expenses
| 148.081 | 110.871 | 96.613 | 57.923 | 53.223 | 45.947 | 27.099 | 23.843 | 17.314 | 9.893 | 5.631 | 3.371 |
| Operating Income
| -148.897 | -110.871 | -96.613 | -57.923 | -40.533 | -29.82 | -18.705 | -22.339 | -15.181 | -8.089 | -5.216 | -1.833 |
| Operating Income Ratio
| 0 | 0 | 0 | -4.564 | -3.194 | -1.849 | -2.228 | -14.853 | -7.117 | -4.484 | -12.569 | -1.192 |
| Total Other Income Expenses Net
| 13.801 | 17.964 | 14.274 | 11.679 | 11.293 | 7.731 | 2.818 | 3.7 | 3.695 | 0.844 | -0.059 | 0.035 |
| Income Before Tax
| -135.096 | -92.907 | -82.339 | -46.244 | -29.24 | -20.692 | -15.805 | -18.603 | -11.436 | -7.226 | -5.678 | -2.053 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -3.644 | -2.304 | -1.283 | -1.883 | -12.369 | -5.361 | -4.006 | -13.682 | -1.335 |
| Income Tax Expense
| -8.452 | -18.054 | -13.827 | -1.75 | -0.124 | 0.124 | -1.326 | -5.107 | -5.406 | -0.863 | 0.462 | 0.22 |
| Net Income
| -126.644 | -74.853 | -68.512 | -44.494 | -29.116 | -20.816 | -15.805 | -18.603 | -11.436 | -7.226 | -5.678 | -2.053 |
| Net Income Ratio
| 0 | 0 | 0 | -3.506 | -2.294 | -1.291 | -1.883 | -12.369 | -5.361 | -4.006 | -13.682 | -1.335 |
| EPS
| -3.44 | -2.68 | -2.8 | -2.33 | -1.64 | -1.38 | -1.53 | -4 | -19.34 | -27.44 | -7.83 | -2.83 |
| EPS Diluted
| -3.44 | -2.68 | -2.8 | -2.33 | -1.64 | -1.38 | -1.53 | -4 | -19.34 | -27.44 | -7.83 | -2.83 |
| EBITDA
| -148.081 | -110.243 | -94.512 | -58.233 | -39.654 | -29.491 | -16.951 | -23.67 | -16.809 | -8.051 | -5.246 | -1.759 |
| EBITDA Ratio
| 0 | 0 | 0 | -4.589 | -3.125 | -1.829 | -2.019 | -15.738 | -7.88 | -4.463 | -12.641 | -1.144 |